Literature DB >> 6477838

Depletion of excessive liver iron stores with desferrioxamine.

A Cohen, M Martin, E Schwartz.   

Abstract

To determine the therapeutic effect of long-term, intensive iron chelation therapy, we studied liver iron content and histology in four children with thalassaemia major during 52-83 months of intensive therapy with desferrioxamine. The initial biopsies obtained prior to or within 21 months after beginning chelation therapy had Grade IV iron staining, with heavy iron deposition present in parenchymal and reticuloendothelial cells. Subsequent biopsies, obtained when serum ferritin levels had fallen to 71-246 micrograms/l, contained Grade 0 or Grade I stainable iron. Little or no iron was present in parenchymal or reticuloendothelial cells. The liver iron concentration, measured by magnetic susceptibility, returned to normal or nearly normal levels. Hepatic fibrosis did not progress during treatment with desferrioxamine. These findings demonstrate that intensive and sustained chelation therapy with desferrioxamine will remove excessive liver iron and preserve hepatocellular structure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6477838     DOI: 10.1111/j.1365-2141.1984.tb06096.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine.

Authors:  V De Sanctis; A Pinamonti; A Di Palma; M Sprocati; G Atti; M R Gamberini; C Vullo
Journal:  Eur J Pediatr       Date:  1996-05       Impact factor: 3.183

Review 2.  An update on iron chelation therapy.

Authors:  Erika Poggiali; Elena Cassinerio; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

3.  Liver injury due to iron overload in thalassemia: histopathologic and ultrastructural studies.

Authors:  K Thakerngpol; S Fucharoen; P Boonyaphipat; K Srisook; S Sahaphong; V Vathanophas; T Stitnimankarn
Journal:  Biometals       Date:  1996-04       Impact factor: 2.949

Review 4.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

5.  Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.

Authors:  M A Aldouri; B Wonke; A V Hoffbrand; D M Flynn; M Laulicht; L A Fenton; P J Scheuer; C C Kibbler; C A Allwood; D Brown
Journal:  J Clin Pathol       Date:  1987-11       Impact factor: 3.411

6.  Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model.

Authors:  Marian L Kruzel; Jeffrey K Actor; Zsolt Radak; Attila Bacsi; Alfredo Saavedra-Molina; Istvan Boldogh
Journal:  Innate Immun       Date:  2009-09-01       Impact factor: 2.680

7.  Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.

Authors:  Janet L Kwiatkowski
Journal:  J Blood Med       Date:  2011-09-21

Review 8.  Iron overload in patients with myelodysplastic syndromes.

Authors:  Peter-D Jensen
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 4.213

Review 9.  A risk-benefit assessment of iron-chelation therapy.

Authors:  J B Porter
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.228

10.  Oxidation-Induced Degradable Nanogels for Iron Chelation.

Authors:  Zhi Liu; Yan Wang; Max Purro; May P Xiong
Journal:  Sci Rep       Date:  2016-02-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.